Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
information fournie par Boursorama CP 20/10/2025 à 08:30

Ajouter Boursorama à vos sources

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions

Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy


Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors.

.../...

Valeurs associées

TRANSGENE
0,7140 EUR Euronext Paris -1,11%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
102,54 -0,93%
CAC 40
7 835,31 -1,62%
HAFFNER ENERGY
0,77 -3,75%
SOCIETE GENERALE
66,08 -5,00%
DBT
0,0936 +23,48%
Chargement...

Pages les plus populaires

L'offre BoursoBank